1 completed, 1 not yet recruiting, 1 unknown. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 1, Not yet recruiting 1, Unknown 1 |
| Phase 1 | 1 | Unknown 1 |
Follow T2D: new trials by email Literature Review of T2D trials Research Report on T2D
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adding Acetazolamide on Top of SGLT2 Inhibition in Persons With Type 2 Diabetes Acetazolamide 62.5 mg, Acetazolamide 125 mg, Acetazolamide 250 mg - T2D | Phase 2 | Not yet recruiting | University Health Network, Toronto | 20 | 2026-12-01 | 2026-10-29 |
| A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes Tirzepatide, Placebo - Overweight, Obesity | Phase 2 | Completed | Eli Lilly and Company | 134 | 2023-02-08 | 2026-09-11 |
| BM-MNC and UCMSC for Type 2 Diabetes Mellitus Patients Bone-marrow aspiration, Intra-pancreatic Catheterisation of BM-MNC, Intravenous Infusion of UC-MSC - T2D | Phase 1 / Phase 2 | Unknown | Universitas Indonesia | 15 | 2016-03-14 | 2020-08-06 |
Diabetes Mellitus, Type 2 (2) · Obesity (1) · Overweight (1) · Renal Insufficiency, Chronic (1)
Diabetes Mellitus (2) · Endocrine System Diseases (2) · Glucose Metabolism Disorders (2) · Metabolic Diseases (2) · Nutritional and Metabolic Diseases (2) · Body Weight (1) · Chronic Disease (1) · Disease Attributes (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Kidney Diseases (1) · Male Urogenital Diseases (1) · Nutrition Disorders (1) · Overnutrition (1) · Pathologic Processes (1)
Acetazolamide (1) · Tirzepatide (1) · dapagliflozin (1)
Eli Lilly and Company (1) · Universitas Indonesia (1) · University Health Network, Toronto (1)
Canada (2) · Austria (1) · Denmark (1) · Indonesia (1) · Mexico (1) · Netherlands (1) · United States (1)
David Z.I Cherney, MD CM, PhD, FRCPC (1)
PMID 26794657, PMID 31214172, PMID 39963952, PMID 40512543
2023 (1)